The inhibitors o In addition, the connection between cancer metabolism and resistance to immunotherapy suggests potential benefit for combined targeting of tumor glycolysis and PD-1/PD-L1 axis (Koukourakis et al., 2005; Vaupel and Mayer, 2007; Wilson and Hay, 2011; Shehade et al., 2014; Marchiq and Pouyssegur, 2016; Feng et al., 2017). The gene discussed is PDCD1; the disease is cancer.